A clinical trial has recently been launched to evaluate the safety and efficacy of the antiviral drug remdesivir plus the anti-inflammatory drug baricitinib for treatment of SARS-CoV-2 infection. The clinical trial, which is also sponsored by NIAID, represents the next phase of NIAID’s Adaptive COVID-19 Treatment Trial, or ACTT. This new trial, known as ACTT2, will recruit participants with confirmed SARS-CoV-2 infection and evidence of lung involvement. Participants will be randomized to receive either remdesivir plus baricitinib, or remdesivir alone. Among other outcomes, investigators will determine if there are significant differences in recovery time across the two treatment groups. To learn more about the clinical trial, please visit the study site on ClinicalTrials.gov, or search by identifier NCT04280705.
A new investigational vaccine against SARS-CoV-2, ChAdOx1, was recently shown to protect rhesus monkeys from infection with SARS-CoV-2-induced pneumonia. The ChAdOx1 vaccine has proven successful in protecting against Middle East respiratory syndrome (MERS), which is closely related to the novel coronavirus SARS-CoV-2, and was recently modified for use with SARS-CoV-2. Early evaluations of the vaccine in rhesus monkeys revealed that treated animals showed no viral replication in lungs, no pulmonary damage, and significantly reduced respiratory disease, all of which are consistent with protection against SARS-CoV-2-induced pneumonia. These findings were shared ahead of print in order to inform and accelerate the public health response to COVID-19.
An NIA-sponsored study has shown that treatment with a repurposed drug can help mice to lose weight and improve metabolic functioning. This drug, disulfiram, is normally prescribed to treat alcohol addiction, but was investigated in the current study as an off-label means of treating obesity and metabolic dysregulation in mice. Researchers fed middle-aged mice a high-fat diet across a period of 12 weeks, which induced obesity and metabolic dysfunction. Then, they divided the mice into four treatment groups, including: (1) a standard diet group; (2) a high-fat diet group; (3) a high-fat diet + low disulfiram dose group; and (4) a high-fat diet + high disulfiram dose group. Mice in the high-fat diet group continued to gain weight and experience metabolic dysregulation, while those who switched to the standard diet eventually lost weight and saw a return of normal metabolic function. Mice in the two disulfiram groups, however, showed more dramatic weight loss and a near reversal of metabolic damage, including restoration of insulin sensitivity. The research team hypothesized that these benefits may be due to the anti-inflammatory properties of disulfiram, which appeared to protect the mice from the harmful effects of the high-fat diet. The researchers noted that treatment with disulfiram could represent a potential therapy for obesity and related metabolic dysfunction in humans, should clinical trial evidence support it. This study was published in Cell Metabolism.
The 140th meeting of the National Advisory Council on Aging (NACA) will be held on Tuesday, May 26th, 2020. Due to the COVID-19 pandemic, the meeting will be held as a virtual teleconference with a compressed format. The public portion of the meeting will take place from 1:00—2:00 pm ET. Further details on the NACA meeting, including teleconference access information and an agenda, can be found on the NACA webpage.
Friends of NIA submitted it’s request letter to the House Appropriations Committee on March 23, 2020.
The letter attached below, requests asks that federal resources be dedicated to sustain and enhance the timely and promising aging research at NIA and across the National Institutes of Health (NIH). Specifically, FoNIA requests:
- $44.7 billion – a $3 billion increase – in FY 2021 for total spending at NIH, which aligns with the overall recommendation of the Ad Hoc Group for Medical Research;
- Within this amount, an increase of least $500 million specifically dedicated to support cross-Institute aging research at the NIH, including but not limited to biomedical, behavioral and social sciences aging research;
- A minimum increase of $354 million specific to research on Alzheimer’s disease and related dementias (ADRD). The NIA is the primary federal agency supporting and conducting Alzheimer’s disease and related dementias research.